OncoMatch/Clinical Trials/NCT06355037
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Is NCT06355037 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Quercetin and Dasatinib for triple-negative breast cancer.
Treatment: Quercetin · Dasatinib · Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum — This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
Required: ESR1 wild-type
Required: PR (PGR) wild-type
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: chemotherapy — metastatic
disease progression after chemotherapy for metastatic breast cancer (MBC)
Cannot have received: chemotherapy
Treatment with chemotherapy...within 3 weeks prior to initiation of study treatment.
Cannot have received: radiotherapy
Treatment with...radiotherapy...within 3 weeks prior to initiation of study treatment.
Cannot have received: immunotherapy
Treatment with...immunotherapy...within 3 weeks prior to initiation of study treatment.
Cannot have received: surgery
Exception: outpatient clinic surgery excluded
Treatment with...surgery (outpatient clinic surgery excluded) within 3 weeks prior to initiation of study treatment.
Lab requirements
Blood counts
adequate hematologic function, laboratory test results, obtained within 14 days prior to initiation of study treatment
Kidney function
adequate end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment
Liver function
adequate end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment
Adequate hematologic and end-organ function, laboratory test results, obtained within 14 days prior to initiation of study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06355037 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy, immunotherapy disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 wild-type is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR wild-type is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify